Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells

Toxicol Appl Pharmacol. 2017 Dec 15:337:85-94. doi: 10.1016/j.taap.2017.10.015. Epub 2017 Oct 23.

Abstract

Previous studies had shown that xanthatin, a natural xanthanolide sesquiterpene lactone, could induce mitotic arrest and apoptosis in non-small cell lung cancer (NSCLC) cells. Here, we examined whether the DNA damage response (DDR) could be a primary cytotoxic event underlying xanthatin-mediated anti-tumor activity. Using EdU incorporation assay in combination with novel imaging flow cytometry, our data indicated that xanthatin suppressed DNA replication, prevented cells from G2/M entry and increased the spot count of γH2AX nuclear foci. Given that checkpoint kinase 1 (Chk1) represents a core component in DDR-mediated cell cycle transition and the phosphorylation on Ser-345 is essential for kinase activation and function, we surprisingly found xanthatin distinctly modulated Ser-345 phosphorylation of Chk1 in A549 and H1299 cells. Further investigation on Cdc25C/CDK1/CyclinB1 signaling cascade in the absence or presence of pharmacological DDR inhibitors showed that xanthatin directly destabilized the protein levels of Cdc25C, and recovery of p53 expression in p53-deficient H1299 cells further intensified xanthatin-mediated inhibition of Cdc25C, suggesting p53-dependent regulation of Cdc25C in a DDR machinery. Moreover, exogenous expression of Cdc25C was also substantially repressed by xanthatin and partially impaired xanthatin-induced G2 arrest. In addition, xanthatin could induce accumulation of ubiquitinated Cdc25C without undergoing further proteasomal degradation. However, an alternative lysosomal proteolysis of Cdc25C was observed. Interestingly, lysosome-like vesicles were produced upon xanthatin treatment, accompanied by rapid accumulation of lysosomal associated membrane protein LAPM-1. Furthermore, vacuolar proton (V)-ATPases inhibitor bafilomycin A1 and lysosomal proteases inhibitor leupeptin could remarkably overturn the levels of Cdc25C in xanthatin-treated H1299 cells. Altogether, these data provide insight into how xanthatin can be effectively targeted DDR molecules towards certain tumors.

Keywords: Cdc25C; Chk1; DNA damage response; Lysosomal proteolysis; Xanthatin.

MeSH terms

  • A549 Cells
  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Checkpoint Kinase 1 / metabolism*
  • DNA Damage*
  • DNA Replication / drug effects
  • Dose-Response Relationship, Drug
  • Enzyme Stability
  • Furans / pharmacology*
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Histones / metabolism
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Lysosomal Membrane Proteins / metabolism
  • Lysosomes / drug effects*
  • Lysosomes / enzymology
  • Phosphorylation
  • Proteolysis
  • Time Factors
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • Ubiquitination
  • Vacuolar Proton-Translocating ATPases / metabolism
  • cdc25 Phosphatases / genetics
  • cdc25 Phosphatases / metabolism*

Substances

  • Antineoplastic Agents
  • Furans
  • H2AX protein, human
  • Histones
  • LAMP1 protein, human
  • Lysosomal Membrane Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • xanthatin
  • CHEK1 protein, human
  • Checkpoint Kinase 1
  • CDC25C protein, human
  • cdc25 Phosphatases
  • Vacuolar Proton-Translocating ATPases

Grants and funding